44 Wealth Management LLC Decreases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

44 Wealth Management LLC trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,945 shares of the biopharmaceutical company’s stock after selling 216 shares during the quarter. 44 Wealth Management LLC’s holdings in Gilead Sciences were worth $272,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of GILD. HHM Wealth Advisors LLC increased its holdings in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 154 shares during the last quarter. Valued Wealth Advisors LLC increased its holdings in shares of Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 161 shares during the last quarter. YANKCOM Partnership acquired a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $28,000. Decker Retirement Planning Inc. acquired a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $29,000. Finally, Crews Bank & Trust acquired a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $31,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $109.95 on Friday. The stock has a market cap of $137.03 billion, a P/E ratio of 297.16, a price-to-earnings-growth ratio of 0.71 and a beta of 0.18. The company has a fifty day simple moving average of $95.41 and a 200-day simple moving average of $88.73. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $111.03. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Equities analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be given a $0.79 dividend. The ex-dividend date is Friday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a yield of 2.87%. Gilead Sciences’s payout ratio is 832.43%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on GILD shares. BMO Capital Markets raised their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. DZ Bank upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target for the company in a report on Thursday, February 13th. Maxim Group downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Mizuho lifted their target price on shares of Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Finally, Citigroup began coverage on shares of Gilead Sciences in a report on Thursday, November 14th. They issued a “buy” rating and a $125.00 target price for the company. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and a consensus price target of $102.08.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares in the company, valued at approximately $7,427,227.92. The trade was a 67.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction on Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the transaction, the chief financial officer now owns 138,919 shares in the company, valued at approximately $12,886,126.44. This represents a 64.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 713,000 shares of company stock valued at $67,945,181 over the last ninety days. Insiders own 0.16% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.